A mouse melanoma model showed that licofelone, a dual COX/5-lipoxygenase (5-LOX) inhibitor, improves therapeutic vaccine efficacy by suppressing Gr-1+CD11b+ MDSC generation and minimizing IL-6 and IL-10 production (Neumann et al., 2016). This evidence concerns the gene ITGAM and melanoma.